Respicardia Announces Highmark Coverage for the remedē® System in Patients with Central Sleep Apnea Expanded insurance coverage now available in Pennsylvania, Delaware and West Virginia News provided by Share this article Share this article MINNETONKA, Minn., Jan. 7, 2021 /PRNewswire/ -- Respicardia, Inc., the manufacturer of the only FDA-approved active implantable system for the treatment of central sleep apnea (CSA), announced today that Highmark Blue Cross Blue Shield and its affiliates will provide coverage for the Company's remedē® System therapy, effective immediately. Highmark provides health insurance coverage to over 5 million individuals across Pennsylvania, Delaware and West Virginia. The remedē® System "We are pleased by this coverage decision from Highmark as it provides needed member access to this proven therapy option" said Peter Sommerness, CEO of Respicardia. "With published clinical data demonstrating sustained safety and efficacy treating CSA through 36 months, we are encouraged by these updated coverage policies that now include the